Endpoint | Factor | HR (95% CI) | P a |
---|---|---|---|
LRFS | |||
 | AKR1C4 + EBV DNA |  |  |
 | Intermediate risk vs. low | 5.182 (1.451–18.505) | 0.011 |
 | High risk vs. low | 7.596 (1.736–33.248) | 0.007 |
 | T stage (4 vs. 1/2/3) | 6.102 (0.740–50.285) | 0.093 |
 | N stage (2/3 vs. 0/1) | 1.245 (0.498–3.114) | 0.640 |
 | Disease stage (IVa vs. I/II/III) | 0.377 (0.046–3.097) | 0.364 |
 | BMI (≥ 18.5 vs. < 18.5 kg/m2) | 0.465 (0.099–2.181) | 0.331 |
 | Smoking history (yes vs. no) | 1.752 (0.746–4.114) | 0.198 |
OS | |||
 | AKR1C4 + EBV DNA |  |  |
 | Intermediate risk vs. low | 2.345 (0.985–5.581) | 0.054 |
 | High risk vs. low | 3.567 (1.380–9.224) | 0.009 |
 | T stage (4 vs. 1/2/3) | 3.425 (1.121–10.471) | 0.031 |
 | N stage (2/3 vs. 0/1) | 3.863 (1.717–8.693) | 0.001 |
 | Disease stage (IVa vs. I/II/III) | 0.781 (0.248–2.461) | 0.673 |
 | BMI (≥ 18.5 vs. < 18.5 kg/m2) | 0.378 (0.146–0.979) | 0.045 |
 | Smoking history (yes vs. no) | 1.577 (0.806–3.806) | 0.183 |
PFS | |||
 | AKR1C4 + EBV DNA |  |  |
 | Intermediate risk vs. low | 2.310 (1.172–4.552) | 0.016 |
 | High risk vs. low | 3.601 (1.688–7.684) | 0.001 |
 | T stage (4 vs. 1/2/3) | 2.588 (1.091–4.603) | 0.031 |
 | N stage (2/3 vs. 0/1) | 2.520 (1.379–4.603) | 0.003 |
 | Disease stage (IVa vs. I/II/III) | 0.976 (0.407–2.340) | 0.956 |
 | BMI (≥ 18.5 vs. < 18.5 kg/m2) | 0.518 (0.223–1.201) | 0.125 |
 | Smoking history (yes vs. no) | 1.679 (0.996–2.830) | 0.052 |
DMFS | |||
 | AKR1C4 + EBV DNA |  |  |
 | Intermediate risk vs. low | 1.835 (0.820–4.106) | 0.140 |
 | High risk vs. low | 2.993 (1.248–7.176) | 0.014 |
 | T stage (4 vs. 1/2/3) | 1.851 (0.752–4.559) | 0.181 |
 | N stage (2/3 vs. 0/1) | 4.009 (1.798–8.937) | 0.001 |
 | Disease stage (IVa vs. I/II/III) | 1.456 (0.569–3.727) | 0.433 |
 | BMI (≥ 18.5 vs. < 18.5 kg/m2) | 0.383 (0.159–0.919) | 0.032 |
 | Smoking history (yes vs. no) | 1.655 (0.886–3.091) | 0.114 |